SCHEDULE: LSP 7 Boosts Stake in AgomAb Therapeutics to 10.6%

LSP 7 Cooperatieve U.A. and LSP 7 Management B.V. have disclosed a 10.6% beneficial ownership in AgomAb Therapeutics NV following an IPO and additional share purchases.

Summary

• LSP 7 Cooperatieve U.A. and LSP 7 Management B.V. (Reporting Persons) beneficially own 5,141,992 Common Shares of AgomAb Therapeutics NV, representing 10.6% of the outstanding shares.
• Prior to the IPO, LSP 7 invested approximately Euro 40 million to purchase 185,585 preferred shares.
• Upon the IPO's consummation on February 9, 2026, a 1-for-21.6450216450216 forward stock split occurred, and LSP 7's preferred stock converted into 4,016,992 Common Shares.
• On the IPO closing date, LSP 7 further purchased 1,125,000 American Depositary Shares (each representing one Common Share) at $16.00 per share, totaling $18,000,000.00.
• The funds for these transactions came from capital contributions by LSP 7's members.
• LSP 7 entered into a Shareholders' Agreement on November 4, 2024, granting registration rights for certain securities, which largely terminated upon IPO except for confidentiality and registration rights.
• A 180-day lock-up agreement was also signed, restricting LSP 7 from selling or disposing of Common Shares or convertible securities post-IPO closing.
• Reporting Persons intend to continuously review their investment and may engage in discussions regarding potential extraordinary corporate transactions, including mergers, take-privates, asset sales, or changes to capitalization, dividend policy, management, or board composition.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it indicates a significant institutional investor's strong commitment and confidence in AgomAb Therapeutics NV through a substantial investment and board representation, despite the potential for future strategic changes.

Positives

• A significant institutional investor, LSP 7, has increased its stake to 10.6%, indicating confidence in AgomAb Therapeutics NV's future.
• LSP 7's designee, Felice Verduyn-van Weegen, is on the Issuer's board, providing direct influence and oversight.
• The investment includes a substantial cash injection of $18 million through the purchase of ADSs at the IPO price of $16.00 per share.

Negatives

• The 180-day lock-up agreement restricts LSP 7 from selling shares, potentially limiting liquidity for this large shareholder in the short term.
• The filing mentions potential consideration of "extraordinary corporate transactions" such as mergers, reorganizations, or take-private transactions, which could lead to de-listing or de-registration of Common Shares, potentially impacting public shareholders.

Risks

• The Reporting Persons may acquire additional securities, retain, or sell all or a portion of their holdings, which could impact share price volatility.
• Potential for extraordinary corporate transactions (e.g., merger, reorganization, take-private transaction) could result in de-listing or de-registration of Common Shares, affecting public shareholders' investment options.
• Changes to the Issuer's capitalization or dividend policy could alter shareholder returns.
• Changes in management or the composition of the Board could introduce uncertainty regarding future strategic direction.

Future Outlook

The Reporting Persons intend to continuously review their investment in AgomAb Therapeutics NV and may, at any time, acquire additional securities, retain or sell existing holdings. They may also engage in discussions with management and the Board regarding potential extraordinary corporate transactions, including mergers, reorganizations, take-private transactions, asset sales, or changes to capitalization, dividend policy, management, or board composition.

Industry Context

StockSavvy.ai notes that a significant stake acquisition by a specialized life sciences investor like LSP 7, particularly around an IPO, often signals strong confidence in the company's pipeline and market potential within the biotechnology sector. This move aligns with a trend of institutional investors seeking early-stage growth opportunities in innovative biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders: The significant stake by LSP 7 and their board representation could provide stability and strategic guidance. However, the potential for "extraordinary corporate transactions" could lead to changes in the company's structure or listing status, impacting public shareholders. The lock-up agreement temporarily limits selling pressure from a major investor.
• Company (AgomAb Therapeutics NV): Benefits from the capital raised during the IPO, including LSP 7's $18 million investment. Gains a significant, engaged institutional investor with board representation.

Next Steps

• LSP 7 will continue to review its investment in AgomAb Therapeutics NV on an ongoing basis.
• LSP 7 may acquire additional securities or sell existing holdings, subject to the 180-day lock-up agreement.
• LSP 7, through its board designee, may engage in discussions with management and the Board regarding potential extraordinary corporate transactions or changes to the company's structure.
• The 180-day lock-up period for LSP 7's shares will expire around August 8, 2026.
• Registration rights granted under the Shareholders' Agreement will terminate upon the earliest of a liquidity event, Rule 144 availability without limitation, or the third anniversary of the IPO (February 9, 2029).

Key Dates

Recommendation

The filing indicates strong institutional confidence in AgomAb Therapeutics NV through LSP 7's significant 10.6% stake and additional investment during the IPO. The presence of a board designee from LSP 7 suggests active engagement. However, the 180-day lock-up period and the stated intent to explore 'extraordinary corporate transactions' introduce both potential upside from strategic initiatives and uncertainty regarding the company's long-term public market status. Given these balanced factors, a 'hold' recommendation is appropriate for investors to monitor developments post-IPO and during the lock-up period.

Keywords

AgomAb Therapeutics NV, LSP 7, Schedule 13D, Beneficial Ownership, IPO, Common Shares, American Depositary Shares, Biotechnology, Life Sciences Investment, Shareholders' Agreement, Lock-Up Agreement, Corporate Governance, Institutional Investment